Could Stay-at-Home Stocks Stay Strong in 2022 Amid the Omicron Scare?
Stay-at-home stocks have looked strong after the emergence of the omicron variant of COVID-19. Which are the best buys for 2022?
![Mohit Oberoi, CFA - Author](https://media.marketrealist.com/brand-img/pppqdpLpM/200x200/img_20191127_192656-mohit-oberoi-1595895293961.jpg)
Dec. 20 2021, Published 7:41 a.m. ET
![Stay-at-home warning amid omicron scare](https://media.marketrealist.com/brand-img/DQxImPHbH/480x251/stay-at-home-stocks-2022-1640001359085.jpg?position=top 480w, https://media.marketrealist.com/brand-img/DQxImPHbH/640x335/stay-at-home-stocks-2022-1640001359085.jpg?position=top 640w, https://media.marketrealist.com/brand-img/DQxImPHbH/768x402/stay-at-home-stocks-2022-1640001359085.jpg?position=top 768w, https://media.marketrealist.com/brand-img/DQxImPHbH/1024x536/stay-at-home-stocks-2022-1640001359085.jpg?position=top 1024w, https://media.marketrealist.com/brand-img/DQxImPHbH/1280x670/stay-at-home-stocks-2022-1640001359085.jpg?position=top 1280w, https://media.marketrealist.com/brand-img/DQxImPHbH/1440x753/stay-at-home-stocks-2022-1640001359085.jpg?position=top 1440w, https://media.marketrealist.com/brand-img/DQxImPHbH/1600x837/stay-at-home-stocks-2022-1640001359085.jpg?position=top 1600w, https://media.marketrealist.com/brand-img/DQxImPHbH/2160x1130/stay-at-home-stocks-2022-1640001359085.jpg?position=top 2160w)
Stay-at-home stocks whipsawed in 2021, hitting new highs at the beginning of the year but then falling amid higher bond yields. More recently, however, with the identification of the omicron variant, stay-at-home stocks have regained momentum.
Despite this turnaround, most stay-at-home stocks are still down this year. What’s their 2022 forecast? Could they recover as COVID-19's omicron variant spreads?
Vaccines aren't very effective against the omicron variant
While the medical community is still studying how effective current vaccines are against the omicron variant, preliminary research shows that some—namely AstraZeneca, Johnson & Johnson, and Chinese and Russian vaccines—offer almost no defense against the omicron variant. Moderna's and Pfizer's appear effective with a booster shot. Although the omicron variant seems a lot less lethal than other variants, many countries are imposing restrictions to slow omicron's spread.
![omicron variant impacts stock markets](https://media.marketrealist.com/brand-img/IXu1Zg7Px/480x320/omicron-variant-impacts-stock-markets-1640001468529.jpg 480w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/640x427/omicron-variant-impacts-stock-markets-1640001468529.jpg 640w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/768x512/omicron-variant-impacts-stock-markets-1640001468529.jpg 768w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/1024x683/omicron-variant-impacts-stock-markets-1640001468529.jpg 1024w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/1280x854/omicron-variant-impacts-stock-markets-1640001468529.jpg 1280w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/1440x960/omicron-variant-impacts-stock-markets-1640001468529.jpg 1440w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/1600x1067/omicron-variant-impacts-stock-markets-1640001468529.jpg 1600w, https://media.marketrealist.com/brand-img/IXu1Zg7Px/2160x1440/omicron-variant-impacts-stock-markets-1640001468529.jpg 2160w)
Stay-at-home stocks in demand after the omicron variant
Stay-at-home stocks were having a dismal year before the omicron variant's emergence, with Peloton, DocuSign, Teladoc Health, Zoom Video Communications, and Chegg falling to new lows.
![zoom video communication revenue growth has slowed down](https://media.marketrealist.com/brand-img/LezrVcPs_/480x252/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 480w, https://media.marketrealist.com/brand-img/LezrVcPs_/640x335/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 640w, https://media.marketrealist.com/brand-img/LezrVcPs_/768x402/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 768w, https://media.marketrealist.com/brand-img/LezrVcPs_/1024x536/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 1024w, https://media.marketrealist.com/brand-img/LezrVcPs_/1280x670/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 1280w, https://media.marketrealist.com/brand-img/LezrVcPs_/1440x754/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 1440w, https://media.marketrealist.com/brand-img/LezrVcPs_/1600x838/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 1600w, https://media.marketrealist.com/brand-img/LezrVcPs_/2160x1131/zoom-video-communication-revenue-growth-has-slowed-down-1640001561090.jpeg 2160w)
The markets’ reaction isn't hard to understand. Stay-at-home companies' top-line growth in 2021 has been a fraction of their growth in 2020. Zoom, for instance, reported revenue growth of 88 percent in fiscal 2020 (ended Jan. 2020), and then 325 percent the following year as the pandemic boosted demand for its services. The company’s revenue growth is expected to slow to 53.9 percent this fiscal year, and then 16.4 percent in the next.
Will 2022 be any better for stay-at-home stocks?
Some stay-at-home companies have become an indispensable part of our lives. The world seems headed for a hybrid model, where working from home and office move hand-in-hand. Similarly, home gyms could coexist with gyms, with the two complementing each other.
After their dismal 2021, stay-at-home stocks are set to fare better in 2022. These companies won't face the tough year-over-year comps they did in 2021, and the spread of the omicron variant should revive demand and boost market sentiment. Some stay-at-home stocks also look quite attractive from a valuation perspective.
Which stay-at-home stocks should you buy in 2022?
Amazon is the top 2022 stay-at-home pick for many analysts. Zoom Video Communications is another stay-at-home stock that should perform well.
Other stay-at-home stocks with a strong outlook include Teladoc Health, which should benefit from the digitization of the healthcare market, and Peloton. Despite its slowing growth and struggle to control damage to its brand after a fatal accident, the exercise equipment maker looks like a good buy at its current valuation.